Here you will find webpage news and updates related to Huntington Disease clinical trials and studies.
– January 19th, 2023
After Wave’s positive announcements last September on the Phase 1/2 SELECT-HD trial, we are excited to learn more about the last updates of the study in our upcoming webinar next Thursday 26th, January.
Dr. Ralf Reilmann, founder of the George-Huntington Institute in Muenster, will be presenting an overview of the SELECT-HD trial, which is looking at the safety of the investigational molecule called WVE-003. According to Dr Reilmann “preliminary data suggest WVE-003 is working as intended, reducing the levels of mutant huntingtin while avoiding targeting the healthy protein”.
There will be time for comments and questions after Dr Reilmann’s presentation, in our Q&A session leaded by Danlin Xu, HD Medical Director at Wave, and Marissa Volpe, HD Program Lead at Wave.
Register here for the webinar
January 26th, 2023
– January 12th, 2023
The GENERATION HD2 clinical trial is just about to start recruiting participants in the first of a total of 15 countries and 9 of them are in Europe: Denmark, France, Germany, UK, Poland, Italy, Spain, Portugal and Switzerland. The study aims to enroll 360 participants and evaluate the safety of the investigational drug tominersen in people with early manifest HD.
– January 11th, 2023
The online course aims to upskill participants on how they can effectively advocate in a virtual world by identifying and engaging key stakeholders and developing partnerships, hosting successful online events and developing and disseminating key advocacy messages.
– December 12th, 2022
– December 11th, 2022
We have adapted the HDTrial Finder dictionary to make it easier and more convenient by including it on the different clinical trial pages. Simply click on the highlighted words to find an easy definition.